Redeye raises the likelihood of approval for lecanemab from 55% to 63% and adjusts the price of lecanemab, based on recent developments in the sector. This results in an intrinsic value per share of SEK 265 (208) for BioArctic. Should Clarity AD meet the endpoint about one year from now, BioArctic's value would rise to SEK 374 per share, a market cap of SEK 33bn - a 170% upside from today's share price.